In this episode titled "Vitiligo Pathogenesis: How the JAK-STAT Pathway Drives Melanocyte Destruction," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD explore the immunological underpinnings of vitiligo and how this understanding has revolutionized treatment thinking.
Philip Mease, MD, reviews the APEX trial data supporting guselkumab's expanded FDA label for inhibition of structural joint damage in psoriatic arthritis.
LEADderm, led by Jennifer Soung, MD, helps dermatologists build leadership, AI readiness, and purpose-driven careers—leaving attendees energized, connected, and patient-focused.
Explore cutaneous SCC care from topical therapies and Mohs to adjuvant radiation and PD-1 immunotherapy, guided by shared decisions and profiling.
Learn how cutaneous SCC care shifts from topical therapy to Mohs, radiation, and PD-1 immunotherapy, guided by shared decisions and profiling.
Linda Stein Gold, MD, discusses zasocitinib's safety and efficacy as an oral treatment for plaque psoriasis.
Roman Bronfenbrener, MD, discusses how AI-generated patient diagnoses are reshaping dermatology visits and creating new challenges.
Kord Honda, MD, provides his first-line and adjunct treatment strategies for acne in recognition of Acne Awareness Month.
Linda Stein Gold, MD, reviews the recent LATITUDE Atlas head-to-head trial results showing zasocitinib's superiority over deucravacitinib for plaque psoriasis.
Christopher Bunick, MD, PhD, discusses the FDA's expanded approval of roflumilast cream 0.3% for plaque psoriasis in children as young as 2 years of age.
The panel turns to taking a thorough patient history, performing a complete physical exam, and ordering appropriate laboratory workup when evaluating a patient with vitiligo.
In this episode, “Understanding Corticosteroid Risks in Inflammatory Dermatoses,” the expert faculty explore the key findings from a recent consensus paper evaluating the risks associated with topical and systemic corticosteroid therapy and the role of advanced targeted topical treatments in inflammatory skin diseases. The panel reviews the methodology behind the expert consensus process, including the comprehensive literature review and evidence-based approach used to develop recommendations for clinical practice.
The panel reviews the first patient case—a 38-year-old woman with recurrent hives and intermittent swelling—highlighting the key clinical criteria that clinch a CSU diagnosis.
A national survey examines the pressures facing independent dermatologists and strategies to strengthen practice performance.
Welcome back to another Dermatology Times Between the Lines series. In this episode titled, “Rethinking Long-Term Management of Inflammatory Dermatoses,” the expert faculty discuss the chronic, relapsing nature of inflammatory skin diseases and how advances in our understanding of underlying inflammation have influenced treatment goals. The panel explores commonly encountered inflammatory dermatoses, including atopic dermatitis, psoriasis, and seborrheic dermatitis, and examines how durable disease control has become an increasingly important objective in clinical practice.
The panel reframe vitiligo as a chronic autoimmune disease affecting 1–2% of the global population, emphasizing its clinical presentations, associated comorbidities, and significant psychosocial impact on patients across all skin types.
The panel reflects on dermatology's evolving role in CSU, from limited options and reluctance to a new era of empowered, effective disease management.
Philip Mease, MD, discusses the FDA's label expansion for guselkumab's inhibition of structural joint damage in psoriatic arthritis.
Learn why gene expression profiling in cutaneous SCC can’t yet guide imaging or radiation decisions—and what evidence gaps still limit its use.
Gene expression profiling flags hidden high-risk cutaneous
Kord Honda, MD, reviews the hormonal drivers of acne, prevention-focused treatment, and common skin care misconceptions.
Raj Chovatiya, MD, PhD, MSCI, co-chair of RAD 2026, highlighted new AD science, type 2 inflammation insights, and emerging therapies—helping clinicians translate immunology advances into better patient care.
Expert guidance from RAD 2026 dispels eczema diet myths, urging symptom-based allergy testing and whole-patient atopic dermatitis care with practical skin, sleep, and lifestyle strategies.
Discover how JAK inhibitors reshape AD care with rapid relief, smart safety screening, and emerging personalized strategies that guide real-world treatment choices.
RNA gene-expression profiling from biopsy stratifies cutaneous squamous cell cancer metastasis risk, guiding surveillance and adjuvant radiation.
Learn when gene expression profiling reshapes cutaneous SCC risk, guiding radiation, imaging, and follow-up beyond traditional staging.
At RAD 2026, Peter Lio, MD, discussed shared decision-making strategies and emerging microbiome-targeted therapies for atopic dermatitis.
Peter Lio, MD, explains how shared decision-making and newer nonsteroidal topicals and systemic options are reshaping pediatric eczema care, easing steroid worries.
Mona Shahriari, MD, FAAD, urges viewing AD as systemic, guiding earlier personalized systemic therapy while optimizing topicals and shared decision-making
David Rosmarin, MD, reviewed the heterogeneous nature of chronic hand eczema, areas of unmet need in atopic dermatitis treatment, and emerging systemic options in the vitiligo pipeline at RAD 2026.
